New dialysis filters aim to cut bleeding risk by reducing heparin use
NCT ID NCT05117450
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two special dialysis membranes (HYDROLINK and HeprAN) to see if they can safely reduce or eliminate the need for heparin, a blood thinner that raises bleeding risk. About 302 adults on long-term hemodialysis will take part. The goal is to complete dialysis sessions without using heparin, lowering the chance of bleeding complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chu Reims
RECRUITINGReims, 51092, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk